Barmicil Comp (Lotrisone) Cream 30g
Contains: Betametasona, Clotrimazol and Gentamicina
THIS IS THE BRAND MEDICATION
THERAPEUTIC INDICATIONS: BARMICIL COMPOUND ® Cream is indicated for the relief of inflammatory manifestations of dermatosis responsive to steroids, complicated by secondary infection caused by organisms sensitive to the components of this preparation dermatological or suspected the possibility of such infection .
Clotrimazole has been shown to be effective in the treatment of tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum and Microsporum canis; candidiasis caused by Candida albicans and tinea versicolor due to Malassezia furfur (Pityrosporon orbiculare).
Bacteria susceptible to the action of gentamicin include sensitive strains of Streptococci (group A beta-hemolytic, alpha hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative and penicillinase producing strains) and Gram-negative bacteria Pseudomonas aeruginosa,Aerobacter aerogenes, Escherichia coli, Proteus vulgaris and Klebsiella pneumoniae.
Action: BARMICIL COMPOUND ® Cream combines the anti-inflammatory, antipruritic and vasoconstrictor sustained betamethasone dipropionate with broad-spectrum antifungal action of clotrimazole and antibiotic effect of gentamicin. Clotrimazole appears to act on the fungal cell membrane, causing loss of cell contents. Gentamicin provides a highly effective topical treatment in primary and secondary bacterial infections of the skin.
CONTRAINDICATIONS: Its use is contraindicated in patients with a history of hypersensitivity to any component of the formula. Not for use in tuberculous lesions of the skin, acute viral infections such as herpes simplex, varicella or during the vaccination period. Should not be used near the eyes.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: Long-term topical use of antibiotics may occasionally result in overgrowth of nonsusceptible microorganisms. To occur or supervene this irritation, hypersensitivity or superinfection with the use of BARMICIL COMPOUND®, should stop treatment and start appropriate therapy.
It has been shown that there is cross-allergenicity among aminoglycosides.
Any side effects associated with systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.
Systemic absorption of topical corticosteroids or gentamicin treated areas will be increased if extensive body surface or if an occlusive dressing is used.
Avoid application of gentamicin in open wounds or damaged skin.
In these circumstances, appropriate measures should be taken, particularly in infants and children.
Not recommended for prolonged use of gentamicin.
BARMICIL COMPOUND ® Cream is not for ophthalmic use.
Should apply a thin layer of cream to cover COMPOUND BARMICIL completely the affected area and surrounding skin twice daily, morning and evening. For treatment to be effective,COMPOUND BARMICIL Cream should be applied regularly.
The duration of treatment varies and depends on the extent and location of the disease, as well as the patient's clinical response.
However, if there is no improvement in three or four weeks, the diagnosis should be considered again.
- Name of medicine: Barmicil
- Comparable patent medicine: Quadriderm
- Active ingredient: Betamethasone / clotrimazole / gentamicin
- Presentation: Cream
- Concentration: 100g
- Extended-release tablets: No
- Lab: Chemistry Sons, Inc. de CV
- Box of 30 g tube
- Made in: Mexico